Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
A randomised therapeutic trial of 13-cis-retinoic acid was carried out in 70 patients with myelodysplastic syndrome having 5% or fewer marrow blast cells. Among non-sideroblastic patients the 1-year survival in the treated group was 77%, compared with 36% in the control group. There were too few deaths among patients with sideroblastic anaemia to allow any effect of therapy on survival to be evaluated.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000756:Anemia, Sideroblastic / Q000188:drug therapy / Q000401:mortality; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007536:Isomerism; D015474:Isotretinoin; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D011897:Random Allocation; D014212:Tretinoin / Q000627:therapeutic use*
D014212:Tretinoin; D015474:Isotretinoin